VisiRose january 2025 Seed Funding Round

VisiRose, a clinical-stage biotechnology company based in Knoxville, Tennessee, has successfully raised $3 million in a seed funding round. The announcement, made on January 16, 2025, marks a significant milestone for the company as it aims to advance its groundbreaking therapies for sight-threatening eye conditions. The identities of the investors involved in this funding round were not disclosed.

The funds will be strategically allocated to support several critical initiatives. A primary focus is the completion of a pre-investigational new drug (IND) submission meeting with the U.S. Food and Drug Administration (FDA). This meeting will center on the company’s Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a non-invasive investigational treatment designed to address infectious keratitis and other serious ocular infections.

Additionally, VisiRose plans to submit an IND application for its investigational drug, PV-305. This treatment leverages photodynamic therapy (PDAT) to combat corneal blindness, a condition that poses significant challenges globally. The company aims to secure FDA acceptance of this application, which would mark a critical step toward clinical trials.